TapewireFind a company

person · Reporting owner

Jaen Juan C.

Disclosed activity across 1 company

Tapewire entity
30815
SEC CIK
0001422996

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arcus Biosciences, Inc.RCUS · Entity 4104PresidentJuly 09, 2026July 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcus Biosciences, Inc.

Report date July 09, 2026 · Filed July 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Trust842,307 Reported balance After 2026-07-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-07-09 · Sale · Disposed 48,502 · Balance 842,307

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Common StockSEC Table I · non-derivativeIndirectBy Trust822,508 Reported balance After 2026-07-10 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-07-10 · Sale · Disposed 19,799 · Balance 822,508

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Common StockSEC Table I · non-derivativeIndirectBy Trust822,240 Reported balance After 2026-07-10 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2026-07-10 · Sale · Disposed 268 · Balance 822,240

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Common StockSEC Table I · non-derivativeDirect378,291 Reported balance Holding disclosure · report date 2026-07-09 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 378,291

F5: Includes the unvested portion of the Reporting Person's RSU grants.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: Includes the unvested portion of the Reporting Person's RSU grants.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 16, 2021 Filed Dec 20, 2021 21:19 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 233 $40.46 $9,426.36
Disclosure

SEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 2

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,265

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.12 to $40.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
December 16, 2021 Filed Dec 20, 2021 21:19 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 632 $39.59 $25,021.89
Disclosure

SEC source: 0001209191-21-070563 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,498

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.11 to $40.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:50 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 2,675 $23.68 $63,344.00
Disclosure

SEC source: 0001209191-21-042075 · doc4.xml · nonDerivative · entry 3

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,286

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.395 to $24.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:50 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 87 $24.77 $2,154.99
Disclosure

SEC source: 0001209191-21-042075 · doc4.xml · nonDerivative · entry 2

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,961

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.63 to $24.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
June 16, 2021 Filed Jun 21, 2021 20:50 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 SaleCommon Stock 2,095 $24.13 $50,552.35
Disclosure

SEC source: 0001209191-21-042075 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,048

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.61 to $24.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:12 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 116,250 $0.00 Strike: $36.73 $0.00
Disclosure

SEC source: 0001209191-21-004270 · doc4.xml · derivative · entry 3

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,250

Underlying: Common Stock · 116,250 shares

Expires 2031-01-18

F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 19, 2021 Filed Jan 20, 2021 21:12 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 19,375 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-004270 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,768

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company.

Read SEC document
October 13, 2020 Filed Oct 15, 2020 20:46 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GiftCommon Stock 1,207,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-054918 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,572,240

F1 · price: Gift to various family trusts over which the reporting person has neither voting nor investment control.

Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantCommon Stock 55,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-034981 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,393

F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company.

Read SEC document
January 17, 2020 Filed Jan 22, 2020 15:49 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 200,000 $0.00 Strike: $10.23 $0.00
Disclosure

SEC source: 0001209191-20-004401 · doc4.xml · derivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-12-31

F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2020, subject to the Reporting Person's continued service to the Company.

Read SEC document
June 28, 2019 Filed Jun 28, 2019 23:07 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 4,894 $7.89 $38,636.66
Disclosure

SEC source: 0001209191-19-039547 · doc4.xml · nonDerivative · entry 2

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,779,240

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.69 to $8.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 27, 2019 Filed Jun 28, 2019 23:07 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 10,106 $7.44 $75,216.94
Disclosure

SEC source: 0001209191-19-039547 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,774,346

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.32 to $7.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 03, 2019 Filed Jun 4, 2019 19:44 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 10,000 $8.25 $82,485.00
Disclosure

SEC source: 0001209191-19-034201 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,764,240

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.05 to $8.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
January 16, 2019 Filed Jan 18, 2019 18:03 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 GrantStock Option (right to buy) · Derivative 200,000 $0.00 Strike: $10.36 $0.00
Disclosure

SEC source: 0001209191-19-004478 · doc4.xml · derivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-01-15

F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 16, 2019, subject to the Reporting Person's continued service to the Company.

Read SEC document
November 13, 2018 Filed Nov 15, 2018 18:21 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 10,000 $11.80 $118,039.00
Disclosure

SEC source: 0001209191-18-058692 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,754,240

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.64 to $12.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 13, 2018 Filed Aug 13, 2018 21:41 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 3,159 $11.77 $37,168.16
Disclosure

SEC source: 0001209191-18-046476 · doc4.xml · nonDerivative · entry 3

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,744,240

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.61 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 10, 2018 Filed Aug 13, 2018 21:41 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 2,579 $11.94 $30,796.35
Disclosure

SEC source: 0001209191-18-046476 · doc4.xml · nonDerivative · entry 2

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,741,081

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.87 to $12.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
August 09, 2018 Filed Aug 13, 2018 21:41 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 4,262 $11.93 $50,855.46
Disclosure

SEC source: 0001209191-18-046476 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,738,502

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.41 to $12.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionSeries C Convertible Preferred Stock · Derivative 29,936 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007987 · doc4.xml · derivative · entry 6

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 29,936 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F5 · derivative.underlying_shares: Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionSeries B Convertible Preferred Stock · Derivative 125,012 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007987 · doc4.xml · derivative · entry 5

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 125,012 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionSeries A Convertible Preferred Stock · Derivative 2,020,202 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007987 · doc4.xml · derivative · entry 4

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 2,020,202 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.exercise_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

F2 · derivative.expiration_date: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 PurchaseCommon Stock 66,666 $15.00 $999,990.00
Disclosure

SEC source: 0000899243-18-007987 · doc4.xml · nonDerivative · entry 2

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,734,240

F3 · shares: Represents shares purchased in the Issuer's initial public offering.

Read SEC document
March 19, 2018 Filed Mar 19, 2018 21:27 UTC Arcus Biosciences, Inc. RCUS · Entity 4104 ConversionCommon Stock 2,175,150 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-007987 · doc4.xml · nonDerivative · entry 1

Jaen Juan C. · CIK 0001422996 · Director · President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 2,667,574

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.

F2 · price: The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.